Commentary : Pharmacologic Correlates that Address the Clinicopathobiology of COVID-19
© 2020 by the Association of Clinical Scientists, Inc..
COVID-19 could remain a pandemic until we get a SARS-CoV-2 vaccine to immunize the world population. In the interim, we have the opportunity to consider its clinicopathobiology in the context of the pharmacologic correlates available from the existing medical literature to prevent the COVID-19 infected patient from progressing into a fatal stage. This commentary serves as a forum for that end and suggests relatively non-toxic therapies that could be applied in a combinatorial fashion for consideration by the physicians and their patients with COVID-19 infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Annals of clinical and laboratory science - 50(2020), 6 vom: 17. Nov., Seite 837-841 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Brown, Robert E [VerfasserIn] |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 29.12.2020 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM318997878 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318997878 | ||
| 003 | DE-627 | ||
| 005 | 20231225170528.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1063.xml |
| 035 | |a (DE-627)NLM318997878 | ||
| 035 | |a (NLM)33334802 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brown, Robert E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Commentary |b Pharmacologic Correlates that Address the Clinicopathobiology of COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.12.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 by the Association of Clinical Scientists, Inc. | ||
| 520 | |a COVID-19 could remain a pandemic until we get a SARS-CoV-2 vaccine to immunize the world population. In the interim, we have the opportunity to consider its clinicopathobiology in the context of the pharmacologic correlates available from the existing medical literature to prevent the COVID-19 infected patient from progressing into a fatal stage. This commentary serves as a forum for that end and suggests relatively non-toxic therapies that could be applied in a combinatorial fashion for consideration by the physicians and their patients with COVID-19 infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a clinicopathobiology | |
| 650 | 4 | |a pharmacology | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Tahseen, Danyal |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of clinical and laboratory science |d 1973 |g 50(2020), 6 vom: 17. Nov., Seite 837-841 |w (DE-627)NLM000096695 |x 1550-8080 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2020 |g number:6 |g day:17 |g month:11 |g pages:837-841 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2020 |e 6 |b 17 |c 11 |h 837-841 | ||